Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV.


Journal

BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690

Informations de publication

Date de publication:
09 09 2023
Historique:
received: 02 11 2022
accepted: 31 08 2023
medline: 11 9 2023
pubmed: 10 9 2023
entrez: 9 9 2023
Statut: epublish

Résumé

In 2018, the Malawi Ministry of Health adopted the recommendation to switch first-line antiretroviral therapy (ART) from an efavirenz (EFV)-based to a dolutegravir (DTG)-based regimen. Little is known about patients' experience during this transition. We conducted a qualitative study to explore DTG-related counselling challenges among providers of HIV care and factors influencing regimen switching or non-switching among women living with HIV in Lilongwe, Malawi. Between February-July 2020, we recruited participants who took part in DTG counselling on reasons to switch, side effects, and benefits from two government health facilities providing HIV care: Area 18 health centre and Bwaila district hospital in Lilongwe, Malawi. We purposively sampled and interviewed 8 women living with HIV who remained on an EFV-based regimen after counselling, 10 women who switched to a DTG-based regimen, and 10 HIV care providers who provided counselling about ART switching. In-depth interviews were used to explore patient's perceptions of DTG, factors affecting the decision to switch, and both patient and provider experience with counselling. Interview data was coded for themes using inductive and deductive codes. Interviews were conducted until thematic saturation was achieved. Data matrices were used for analysis and thematic extraction. Most women in both groups were well versed on DTG's potential side effects and felt well counselled on the benefits of switching, such as quicker viral load suppression. Many women associated DTG with birth defects and expressed concern. However, the primary reason for not switching was concern with how the new medication would be tolerated, especially when they were satisfied with their current regimen. Almost all providers expressed difficulty providing DTG counselling. Primary reasons included feeling inadequately trained and/or not having resources to use during counselling, such as diagrams or brochures. DTG counselling was well accepted by women; however, some felt that their concerns were not fully addressed. Providers reflected this sentiment in that they did not feel adequately trained or well-equipped to provide adequate counselling. Training on counselling for new ART regimens should be intensified and utilize patient-centered educational materials to address the concerns raised by both patients and health care providers.

Identifiants

pubmed: 37689628
doi: 10.1186/s12905-023-02630-7
pii: 10.1186/s12905-023-02630-7
pmc: PMC10492391
doi:

Substances chimiques

dolutegravir DKO1W9H7M1
efavirenz JE6H2O27P8
Benzoxazines 0
Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

478

Subventions

Organisme : FIC NIH HHS
ID : D43 TW010060
Pays : United States

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

BMC Infect Dis. 2021 Nov 13;21(1):1154
pubmed: 34774018
Am Fam Physician. 2011 Oct 1;84(7):780-4
pubmed: 22010616
BMC Public Health. 2019 Oct 28;19(1):1382
pubmed: 31660947
N Engl J Med. 2019 Aug 29;381(9):827-840
pubmed: 31329379
Cost Eff Resour Alloc. 2019 Sep 23;17:20
pubmed: 31572067
Lancet HIV. 2018 Jul;5(7):e400-e404
pubmed: 29884404
BMC Health Serv Res. 2019 Jun 3;19(1):350
pubmed: 31159780
J Biol Chem. 2019 Oct 11;294(41):15137-15157
pubmed: 31467082
Afr J Prim Health Care Fam Med. 2016 Apr 26;8(2):e1-6
pubmed: 27380841
Am J Public Health. 2015 Apr;105(4):665-9
pubmed: 25713962
PLoS One. 2021 Feb 25;16(2):e0247583
pubmed: 33630952
S Afr Med J. 2016 Dec 21;107(1):28-30
pubmed: 28112085
Lancet HIV. 2019 Feb;6(2):e72-e73
pubmed: 30503326

Auteurs

John C Chapola (JC)

University of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi. johnchapola@gmail.com.

Fan Lee (F)

Duke University, Durham, NC, USA.

Agatha Bula (A)

University of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.

Nora E Rosenberg (NE)

University of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Gilling's School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.

Jennifer Tseka (J)

University of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.

Maganizo Chagomerana (M)

University of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Gilling's School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.

Mina C Hosseinipour (MC)

University of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Division of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Jennifer Hui-Yu Tang (JH)

University of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH